Clinical Research Directory

Toxicity of Intensive First-Line Treatment for Adult Burkitt Lymphoma: A Retrospective Observational Study

Burkitt lymphoma is a rare, highly aggressive B-cell non-Hodgkin lymphoma in adults. Although intensive multi-agent chemotherapy can achieve high complete remission rates, it is associated with substantial toxicity, morbidity, and sometimes treatment-related mortality. This retrospective, single-center observational study aims to characterize the short- and long-term complications of intensive first-line treatment in adults with Burkitt lymphoma managed at Strasbourg University Hospitals. The study will evaluate treatment-related toxicities, overall survival at five years, and progression-free survival at 24 months. Secondary objectives include assessing treatment delays, chemotherapy dose reductions, and their associations with toxicity, disease location at diagnosis, and survival. All eligible adult patients diagnosed with Burkitt lymphoma or managed for this condition at Strasbourg University Hospitals and the ICANS between January 1, 2009, and December 31, 2025, will be considered. The study will use retrospective medical record data, with no a priori sample size calculation because of the rarity of the disease and the single-center design.

Epcoritamab in Combination With Dose Adjusted EPOCH-R for High-risk Burkitt Lymphoma (BL), The BEDROCK Study

This phase II trial studies how well epcoritamab works in combination with the chemotherapy regimen dose adjusted etoposide, prednisone, Oncovin (vincristine), cyclophosphamide, hydroxydaunorubicin-rituximab (DA-EPOCH-R) in treating patients with high risk Burkitt lymphoma. Epcoritamab binds to a protein called CD3, which is found on T cells (a type of white blood cell). It also binds to a protein called CD20, which is found on B cells (another type of white blood cell) and some lymphoma cells. This may help the immune system kill cancer cells. Epcoritamab is a type of bispecific T-cell engager. Etoposide is in a class of medications known as podophyllotoxin derivatives. It blocks a certain enzyme needed for cell division and DNA repair and may kill cancer cells. Vincristine is in a class of medications called vinca alkaloids. It works by stopping cancer cells from growing and dividing and may kill them. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's DNA and may kill cancer cells. It may also lower the body's immune response. Doxorubicin is in a class of medications called anthracyclines. Doxorubicin damages the cell's DNA and may kill cancer cells. It also blocks a certain enzyme needed for cell division and DNA repair. Prednisone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs. Giving epcoritamab in combination with the DA-EPOCH-R regimen may be an effective treatment for patients with high risk Burkitt lymphoma.